Merus N.V..
MRUS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Merus N.V. is a clinical-stage immuno-oncology company developing innovative full-length multi-specific antibodies, referred to as Biclonics® and Triclonics®, for cancer treatment. Their focus is on developing antibody-based therapeutics that can redirect the human immune system to attack cancer cel...Show More
Better Health for All
0
No evidence available to assess Merus N.V. on Better Health for All.
Fair Money & Economic Opportunity
0
Merus N.V. is a clinical-stage immuno-oncology company, and its core business does not involve lending, insuring, moving, or storing money for consumers.
1
Therefore, many KPIs related to financial services are not applicable. The company does not offer dedicated inclusion programs related to financial services, nor does it generate or manage customer finance data.
2
It is not regulated as a lender, does not directly impact customer credit or savings outcomes, and does not provide debt products to consumers.
3
Merus also does not operate financial service access points or offer financial products requiring disclosure.
4
While the PTx Assist program provides financial support resources and education on healthcare costs,
5
this is specific to accessing medical products and is not considered financial literacy or inclusion in the context of financial services as defined by the rubric.
Fair Pay & Worker Respect
40
For 2024, the ratio of the Chief Executive Officer's total compensation to the median employee's total compensation was 47 to 1, with the median employee earning $204,923 annually.
1
The company provides 100% covered premiums for health and dental insurance.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles regarding Merus N.V.'s performance on fair trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity initiatives.
1
Honest & Fair Business
-50
Merus N.V. has a formal whistleblower policy that includes a reporting officer, a process for receiving and investigating complaints, and a commitment to confidentiality.
1
A hotline is available for anonymous reporting of accounting and auditing matters.
2
The company's code of conduct prohibits unlawful activity, unfair dealing, and taking corporate opportunities for personal gain, and addresses doing business with others who violate laws or ethical standards.
3
Kind to Animals
-60
Merus N.V. states that certain laws and regulations require animal testing for its bispecific antibody candidates before human clinical trials.
1
The company also uses a patented MeMo® mouse for antibody production in its research.
2
The articles explicitly state that no specific animal testing policy is mentioned.
3
The company acknowledges that animal testing activities have been subject to controversy.
4
No information is provided regarding the number of animals used in testing annually, nor are there transparent reduction targets.
5
No War, No Weapons
0
The provided articles do not contain specific, factual evidence to assess Merus N.V. against any of the KPIs for the 'No War, No Weapons' ethical value. While the company's core business is immuno-oncology for cancer treatment, the rubric requires explicit evidence regarding revenue from arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other defense-related activities or policies. No such information was found in the provided documents.
Planet-Friendly Business
-30
Merus N.V. has no reported environmental compliance violations, regulatory actions, or fines.
1
However, there is no publicly available data for any other Planet-Friendly Business KPIs, including carbon emissions, renewable energy use, water usage, waste diversion, or climate targets.
2
This significant lack of disclosure makes a comprehensive assessment of the company's environmental performance impossible.
Respect for Cultures & Communities
-10
Merus N.V. has no reported cultural appropriation incidents, no specific cultural impact assessment protocol, and FPIC processes are not applicable to its operations.
1
The company also has no reported cultural site disruptions.
2
However, all notices, documentation, and communications are in English, indicating limited local language incorporation.
3
Safe & Smart Tech
0
No evidence available to assess Merus N.V. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific data points related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were provided in the article.
1
The article focuses solely on the company's ESG risk rating.
2